Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry Genetics in a $600 million deal. This move, comprising $375 million in cash and $225 million in stock, signals Tempus AI’s intent to expand its genetic testing capabilities and solidify its leadership in healthcare innovation. This acquisition […]